Dr. René C.-Gaudreault, l. pharm., PhD, is a senior researcher at the Centre de recherche du CHU de Québec-Laval University. He is the director of a medicinal chemistry laboratory based at the Hôpital Saint-François d’Assise. In addition, he is a full professor in the Department of molecular medicine at the Laval University School of Medicine. Dr. C.-Gaudreault is the author and coauthor of over 100 publications in peer-reviewed journals, and the inventor and co-inventor of numerous patents. He is the recipient of several prizes and distinctions, notably the Frisen-Rygel Medal for an outstanding Canadian academic discovery leading to uniquely positioned commercialization opportunities. His research programs mainly focus on the design and development of new anti-inflammatory, antipsoriatic, and anticancer drugs for personalized therapies.

Development of new anticancer and anti-inflammatory drugs for personalized medicine

Cancer and inflammation-based diseases are major health concerns in Canada and worldwide. Despite important medical breakthroughs over the past 75 years, few treatments are efficient and devoid of deleterious effects. Consequently, new drugs and treatments are required to improve both the quality of life and the life expectancy of patients. It is in this context that Dr. Gaudreault’s laboratory is involved in the drug design and development of new anticancer agents and their prodrugs, and non-steroidal anti-inflammatory agents exhibiting suitable biopharmaceutical and pharmacodynamic properties for preclinical and clinical studies. In addition, Dr. Gaudreault’s team is involved in the determination of their mechanisms of action and their potential therapeutical applications, using various cellular and molecular pharmacology approaches to support the design and the optimization of the next generations of molecules. Dr. Gaudreault’s research programs involve several interrelated and complementary disciplines, including molecular design and modelling, medicinal chemistry, cell biology, molecular pharmacology, and animal experimentation. The outcomes of these projects will contribute to new and efficient drugs for applications in personalized medicine.

Hôpital Saint-François d'Assise
10, rue de l'Espinay
E0-171
Québec, Québec
Canada G1L 3L5
38 entries « 1 of 4 »

Fournier MJ, Coudert L, Mellaoui S, Adjibade P, Gareau C, Cote MF, Sonenberg N, Gaudreault RC, Mazroui R

Inactivation of the mTORC1-eukaryotic translation initiation factor 4E pathway alters stress granule formation.

Journal Article

Mol Cell Biol, 33 (11), pp. 2285-301, 2013, ISSN: 0270-7306.

Abstract | Links:

Charest-Morin X, Fortin S, Lodge R, Roy C, Gera L, C-Gaudreault R, Marceau F

Inhibitory effects of cytoskeleton disrupting drugs and GDP-locked Rab mutants on bradykinin B₂ receptor cycling.

Journal Article

Pharmacol Res, 71 , pp. 44-52, 2013, ISSN: 1043-6618.

Abstract | Links:

Turcotte V, Fortin S, Vevey F, Coulombe Y, Lacroix J, Cote MF, Masson JY, C-Gaudreault R

Synthesis, biological evaluation, and structure-activity relationships of novel substituted N-phenyl ureidobenzenesulfonate derivatives blocking cell cycle progression in S-phase and inducing DNA double-strand breaks.

Journal Article

J Med Chem, 55 (13), pp. 6194-208, 2012, ISSN: 0022-2623.

Abstract | Links:

Marceau F, Bawolak MT, Lodge R, Bouthillier J, Gagne-Henley A, C-Gaudreault R, Morissette G

Cation trapping by cellular acidic compartments: beyond the concept of lysosomotropic drugs.

Journal Article

Toxicol Appl Pharmacol, 259 (1), pp. 1-12, 2012, ISSN: 0041-008X.

Abstract | Links:

Fortin S, Wei L, Moreau E, Lacroix J, Cote MF, Petitclerc E, Kotra LP, Gaudreault RC

Substituted phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonamides as antimitotics. Antiproliferative, antiangiogenic and antitumoral activity, and quantitative structure-activity relationships.

Journal Article

Eur J Med Chem, 46 (11), pp. 5327-42, 2011, ISSN: 0223-5234.

Abstract | Links:

Fortin S, Wei L, Moreau E, Lacroix J, Cote MF, Petitclerc E, Kotra LP, C-Gaudreault R

Design, synthesis, biological evaluation, and structure-activity relationships of substituted phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonates as new tubulin inhibitors mimicking combretastatin A-4.

Journal Article

J Med Chem, 54 (13), pp. 4559-80, 2011, ISSN: 0022-2623.

Abstract | Links:

Fortin S, Bouchon B, Chambon C, Lacroix J, Moreau E, Chezal JM, Degoul F, C-Gaudreault R

Characterization of the covalent binding of N-phenyl-N'-(2-chloroethyl)ureas to {beta}-tubulin: importance of Glu198 in microtubule stability.

Journal Article

J Pharmacol Exp Ther, 336 (2), pp. 460-7, 2011, ISSN: 0022-3565.

Abstract | Links:

Patenaude A, Fortin JS, Deschenes R, Cote MF, Lacroix J, C-Gaudreault R, Petitclerc E

Chloroethyl urea derivatives block tumour growth and thioredoxin-1 nuclear translocation.

Journal Article

Can J Physiol Pharmacol, 88 (11), pp. 1102-14, 2010, ISSN: 0008-4212.

Abstract | Links:

Fortin S, Moreau E, Lacroix J, Cote MF, Petitclerc E, C-Gaudreault R

Synthesis, antiproliferative activity evaluation and structure-activity relationships of novel aromatic urea and amide analogues of N-phenyl-N'-(2-chloroethyl)ureas.

Journal Article

Eur J Med Chem, 45 (7), pp. 2928-37, 2010, ISSN: 0223-5234.

Abstract | Links:

Mounetou E, Miot-Noirault E, Gaudreault RC, Madelmont JC

N-4-iodophenyl-N'-2-chloroethylurea, a novel potential anticancer agent with colon-specific accumulation: radioiodination and comparative in vivo biodistribution profiles.

Journal Article

Invest New Drugs, 28 (2), pp. 124-31, 2010, ISSN: 0167-6997.

Abstract | Links:

38 entries « 1 of 4 »
Signaler des ajouts ou des modifications

Active projects

  • Centre de recherche sur le cancer, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1996-05-01 to 2023-04-30
  • Centres hospitaliers universitaires de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
  • Substituted phenyl alkylureas as new potent antipsoriatic drugs: Mechanism of action and structure-activity relationships., Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement, from 2015-07-01 to 2020-06-30
  • Validation of Highly Potent Substituted Phenyl Alkylureas as Antipsoriatic Agents, Subvention, Instituts de recherche en santé du Canada, Subvention Projet, from 2018-04-01 to 2021-03-31

Recently finished projects

  • Comprendre le rôle des cellules immunitaires dans le psoriasis grâce au génie tissulaire, Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement, from 2014-04-01 to 2019-03-31
  • Les phénylimidazolidones, de nouvelles molécules pour le traitement personnalisé des cancers du sein hormono- et chimiorésistants: du laboratoire vers la clinique., Subvention, Fondation de l'Université Laval, from 2015-10-01 to 2019-07-30
Data provided by the Université Laval research projects registery